The panel addressed the role of the buy-side board of directors in mergers and acquisitions (M&A) transactions, focusing on communication between management and the board, evaluation of a transaction in the context of capital allocation, effective strategies for integration of an acquired company, and the keys to being a successful strategic buyer. The panel also highlighted recent M&A trends.
The panel was moderated by Foley Partner Steven Hilfinger as well as Bryan Armstrong of FD/Ashton Partners and Justin Friesen of UBS Securities. Panelists were Chris Brown of TechTeam Global and David Drury of Poblocki Sign Company.
Related Insights
09 December 2024
Events
Milwaukee CLE Week 2024
We are excited to announce Foley's Annual Milwaukee CLE Week! This year's program will feature three days of in-person sessions, focusing on essential business, industry, and ethics topics.
23 October 2024
Health Care Law Today
Private Equity Investments in Oncology: Top Five Things to Know
Although private equity (PE) sponsors have been active investors in the health care services industry for the last decade, PE-backed health care providers today constitute only 4% of the United States health market by revenue.
23 October 2024
Health Care Law Today
GLP-1 Drugs: FDA Sued Over Removing Tirzepatide from the Drug Shortage List
Less than a week after the FDA determined that the shortage of the tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been “resolved” and removed from the FDA’s shortage list, the Outsourcing Facilities Association filed a lawsuit against the FDA relating to the agency’s removal of tirzepatide, from the FDA’s drug shortage list.